Go Pro
NYSEAMERICAN:YCBD

cbdMD Q3 2026 Earnings Report

cbdMD logo
$0.58 -0.02 (-2.68%)
As of 01:27 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Upcoming Event
Earnings Conference Call
cbdMD Q3 2026
00:00 / 00:00
Live Transcript
Follow Audio

cbdMD EPS Results

Actual EPS
N/A
Consensus EPS
-$0.03
Beat/Miss
N/A
One Year Ago EPS
N/A

cbdMD Revenue Results

Actual Revenue
N/A
Expected Revenue
$5.69 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

cbdMD Announcement Details

Quarter
Q3 2026
Time
After Market Closes
Conference Call Date
Thursday, August 13, 2026
Conference Call Time
4:20PM ET

Conference Call Resources

cbdMD Earnings Headlines

cbdMD (YCBD) to Announce Earnings on Wednesday
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More cbdMD Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like cbdMD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on cbdMD and other key companies, straight to your email.

About cbdMD

cbdMD (NYSEAMERICAN:YCBD) (NYSEAMERICAN: YCBD) is a Charlotte, North Carolina–based producer and distributor of hemp-derived cannabidiol (CBD) products. Since its founding in 2018, the company has focused on developing a diverse portfolio of wellness offerings designed for human and pet use. Its product range includes tinctures, capsules, gummies, topicals, and pet-specific formulations, each developed to comply with U.S. Food and Drug Administration (FDA) guidelines for hemp-derived substances.

The company operates a vertically integrated business model, sourcing U.S.-grown hemp and overseeing manufacturing processes in cGMP-certified facilities. Third-party laboratory testing is conducted on every batch to verify potency and ensure products are free of THC or within federally approved limits. cbdMD markets both broad-spectrum and isolate-based formulations, targeting consumers seeking natural alternatives for stress relief, sleep support, and post-exercise recovery.

cbdMD’s distribution network spans e-commerce, major online marketplaces, and brick-and-mortar retailers across the United States, with expanding presence in select international markets. The company partners with pharmacies, specialty wellness stores, and veterinarians to broaden its retail footprint, while its direct-to-consumer website serves as a primary channel for product innovation feedback and subscription services.

Since its listing on the NYSE American exchange, cbdMD has pursued strategic product line extensions and marketing collaborations to drive brand awareness. The company emphasizes quality assurance, regulatory compliance, and ongoing research to support the evolving cannabinoid market and to meet consumer demand for trusted CBD solutions.

View cbdMD Profile